Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Payer Response to Medicare Rebate Policy Changes

A white paper by Health Strategies Group, an Eversana company, which is the leading independent provider of global services to the life sciences industry.

Read More »

Opposites attract: Blurring the lines between small and large molecule manufacturing

This whitepaper assesses the current state of the large molecule sector, and how it may be able to learn from the small molecule industry in terms of its supply chain support infrastructure, as well as its acquisition of staff and the adoption of PAT.

Read More »

Tipping Points of Employer-Sponsored Health Insurance

The American Health Policy Institute (AHPI) released “’Tipping Points’ of Employer-Sponsored Health Insurance,” which examines various factors that could impact broad-based employer-provided health coverage.

Read More »

The Science Behind Biosimilars – Entering a New Era of Biologic Therapy

The American College of Rheumatology published a new white paper, “The Science Behind Biosimilars – Entering a New Era of Biologic Therapy,” providing a comprehensive overview of the scientific, clinical, economic and prescribing issues pertaining to biosimilar use, including efficacy, competition and drug pricing.

Read More »

“Not All Amyloid Beta Therapeutics Are Created Equal”

ProMIS Neurosciences Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced it has issued a new scientific white paper entitled: ‘Not all Amyloid Beta Therapeutics are Created Equal’.

Read More »

Personalized Medicine and Value Assessment Frameworks: Context, Considerations, and Next Steps

In this white paper, PMC contends that most value assessment frameworks could unintentionally undermine the health care community’s push toward more personalized care.

Read More »

2017 U.S. Trends in Aggregate Spend, Disclosure and Transparency

With the focus shifting away from the end reporting, companies have continued to invest in systems and processes that manage “upstream” relationships with healthcare providers and consultants, recognizing that the greater compliance risks center around these relationships than on the reported spend itself.

Read More »

Maximizing Disease and Product Education Efforts in a Digital World

A combination of regulatory conditions, shifts in physician workplace demographics, and an increased reliance of highly specialized sales personnel has steadily eroded the traditional sales reps’ responsibilities and ability to manage the HCP practice relationship as a true SPOC.

Read More »

QuintilesIMS white paper: Large benefit for small numbers

The good news … is that innovation is addressing diseases with high-unmet need such as oncology, autoimmune diseases, and central nervous system (CNS) disorders. But, there is a complicating factor in the economic story: the patient population benefiting from launch brands is becoming smaller.

Read More »

Health Care Trends Impacting Organized Provider Groups

The white paper explores trends and market forces affecting organized provider groups (OPGs) and identifies opportunities for pharmaceutical manufacturers to partner with OPGs to develop mutually beneficial programs addressing areas of shared interest.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom